Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01863732 · ClinicalTrials.gov registry record · Phase 3
Extension in AS: Sustainability of Benefits, Safety and Tolerability
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 274
- Enrollment target
NCT01863732 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 274 participants.
The verdict
NCT01863732, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 274 participants
- Enrollment target
Study Summary
This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as well as to generate additional data on the sustainability of clinical benefits, safety and tolerability during long-term administration of secukinumab.
Interventions
- BIOLOGICAL Secukinumab
- OTHER Placebo (Pbo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2013-11-06 |
| Est. Completion | 2018-03-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01863732
The ClinicalTrials.gov registry entry for NCT01863732 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Secukinumab is the first listed.
NCT01863732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01863732 about?
NCT01863732 is a clinical study titled "Extension in AS: Sustainability of Benefits, Safety and Tolerability". This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as well as to generate additional data on the sustainability of clinical ben...
What is the current status of trial NCT01863732?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2013-11-06. Estimated completion is 2018-03-16.
What interventions are being tested in trial NCT01863732?
The interventions under investigation include: Secukinumab (BIOLOGICAL), Placebo (Pbo) (OTHER).
Who is sponsoring clinical trial NCT01863732?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.